ME01969B - Sredstva za lijecenje poremecaja koji ukljucuju modulaciju receptora rijanodina - Google Patents
Sredstva za lijecenje poremecaja koji ukljucuju modulaciju receptora rijanodinaInfo
- Publication number
- ME01969B ME01969B MEP-2014-147A MEP2014147A ME01969B ME 01969 B ME01969 B ME 01969B ME P2014147 A MEP2014147 A ME P2014147A ME 01969 B ME01969 B ME 01969B
- Authority
- ME
- Montenegro
- Prior art keywords
- diseases
- disorders
- accordance
- group
- pharmaceutical preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/841—Muscles; heart
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
Claims (23)
1. Spoj, naznačen time, da je predstavljen strukturom Formule (I):pri čemuR je COOH;i njihove farmaceutski prihvatljive soli.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je u obliku soli s farmaceutski prihvatljivom kiselinom ili lužinom.
3. Spoj u skladu s patentnim zahtjevom 2, naznačen time, da je sol odabrana iz skupine koja se sastoji od natrija, kalija, magnezija, hemifumarata, hidroklorida i hidrobromida.
4. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je odabran izskupine koja se sastoji od:
5. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je predstavljenstrukturnom Formulom (1):ili njihovom farmaceutski prihvatljivom soli.
6. Spoj u skladu s patentnim zahtjevom 5, naznačen time, da je u obliku solis farmaceutski prihvatljivom kiselinom ili lužinom.
7. Spoj u skladu s patentnim zahtjevom 6, naznačen time, da je sol odabranaiz skupine koja se sastoji od natrija, kalija, magnezija, hemifumarata, hidroklorida i hidrobromida.
8. Spoj u skladu s patentnim zahtjevom 7, naznačen time, da je sol natrijeva sol.
9. Spoj u skladu s patentnim zahtjevom 7, naznačen time, da je sol hemifumaratna sol.
10. Farmaceutski pripravak koji sadrži spoj u skladu s patentnim zahtjevima 1-9, naznačena time, da je u kombinaciji s jednim ili više farmaceutski prihvatljivih ekscipijensa ili nosača.
11. Farmaceutski pripravak u skladu s patentnim zahtjevom 10, naznačen time, da se koristi u liječenju ili prevenciji stanja odabranih is skupine koja se sastoji od srčanih poremećaja i oboljenja, mišićnog umora, poremećaja i bolesti muskuloskeletalnog sustava, poremećaja i bolesti središnjeg živčanog sustava (CNS), kognitivne disfunkcije, nervno-mišićnih poremećaja i oboljenja, poremećaja i bolesti kostiju, tumorske kaheksije, maligne hipertermije, dijabetesa, iznenadne srčane smrti i sindroma iznenadne dječje smrti ili za poboljšanje kognitivne funkcije.
12. Farmaceutski pripravak u skladu s patentnim zahtjevom 10, za uporabu u liječenju ili prevenciji stanja u skladu s patentnim zahtjevom 11, naznačen time, da su srčani poremećaji ili oboljenja odabrani iz skupine koja se sastoji od poremećaja ili bolesti nepravilnog rada srca poput primjerice atrijske i ventrikularne aritmije, atrijske i ventrikularne fibrilacije, atrijske i ventrikularne tahiaritmije, atrijske i ventrikularne tahikardije, kateholaminergičke polimorfne ventrikularne tahikardije (CPVT) te njihovih varijanti izazvanih usljed tjelovježbe; poremećaja i bolesti nepravilnog rada srca izazvanog usljed tjelovježbe; srčanog zatajenja; kongestivnog zatajenja srca; kroničnog zatajenja srca; akutnog zatajenja srca; sistoličkog zatajenja srca; dijastoličkog zatajenja srca; akutne dekompenzacije srca; srčane ishemije/reperfuzijska ozljeda (I/R); kronične opstruktivne plućne bolesti; I/R ozljede usljed srčane angioplastije ili usljed trombolize za liječenje infarkta miokarda (MI); te visokog krvanog tlaka.
13. Farmaceutski pripravak u skladu s patentnim zahtjevom 10 za uporabu u liječenju ili prevenciji u skladu s patentnim zahtjevom 11, naznačen time, da je mišićni zamor uzrokovan bolešću, poremećajem ili stanjem skeletnih mišića.
14. Farmaceutski pripravak u skladu s patentnim zahtjevom 10 za uporabu u liječenju ili prevenciji u skladu s patentnim zahtjevom 11, naznačen time, da je muskuloskeletalni poremećaj, bolest ili stanje odabrano iz skupine koja se sastoji zamora skeletnih mišića izazvanog usljed tjelovježbe; zamora mišića izazvanog usljed produljene ili intenzivne tjelovježbe; kongenitalne miopatije; mišične distrofije poput primjerice Duchenne-ove distrofije mišića (DMD), Becker-ove distrofije mišića (BMD), Limb-Girdle distrofije mišića (LGMD), facioskapulohumeralne mišićne distrofije, miotonične mišične distrofije, kongenitalne mišične distrofije (CMD), distalne mišične distrofije, Emery-Dreifuss-ove mišične distrofije i okulofaringealne mišićne distrofije; spinalne mišićne atrofije (SMA), spinalne i bulbarne mišićne atrofije (SBMA), Zamora mišića povezanog sa starosnom dobi; sarkopenije, bolesti središnje jezgre; tumorske kaheksije; poremećaje mjehura i inkontinencije.
15. Farmaceutski pripravak u skladu s patentnim zahtjevom 10 za uporabu u liječenju ili prevenciji u skladu s patentnim zahtjevom 11, naznačen time, da su poremećaj ili bolesti središnjeg živčanog sustava (CNS) odabrani iz skupine koja se sastoji od Alzheimer-ove bolesti (AD), neuropatije, napadaja, Parkinson-ove bolesti (PD) i Huntington-ove bolesti (HD); i nervno-mišićnih poremećaja i bolesti koje su odabrane iz skupine koja se sastoji od spinocerebelarne ataksije (SCA) i amiotrofna lateralna skleroza (ALS, Lou Gehrig-ova bolest).
16. Farmaceutski pripravak u skladu s patentnim zahtjevom za uporabu u liječenju ili prevenciji u skladu s patentnim zahtjevom 11, naznačen time, da je kognitivna disfunkcija povezana sa stresom ili sa starosnom dobi, ili gdje kognitivna funkcija treba biti poboljšana zbog kratkog pamćenja, dugotrajnog pamćenja, pažnje ili učenja, ili gdje je kognitivna disfunkcija povezana s bolesti ili poremećajem koji je odabran iz skupine koja se sastoji od Alzheimer-ove bolesti (AD), poremećaja pažnje uzrokovanog hiperaktivnošću (ADHD), poremećaja autističnog spektra (ASD), generaliziranog anksioznog poremećaja (GAD), opsesivno-kompulzivnog poremećaja (OCD), Parkinsonove bolesti (PD), post-traumatskog stresnog poremećaja (PTSD), Schizophrenije, bipolarnog poremećaja i unipolarne velike depresije.
17. Farmaceutski pripravak u skladu s patentnim zahtjevom 10 za uporabu u liječenju ili prevenciji u skladu s patentnim zahtjevom 11, naznačen time, da je stanje tumorska kaheksija.
18. Farmaceutski pripravak u skladu s patentnim zahtjevom 17, naznačen time, da je tumorska kaheksija uzrokovana usljed metastaziranja tumora kosti.
19. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-9, ili njihove soli, naznačen time, da se koristi za liječenje ili prevenciju stanja odabranih iz skupine koja se sastoji od srčanih poremećaja ili oboljenja, zamora mišića, poremećaja muskuloskeletalnog sustava, poremećaja i bolesti središnjeg živčanog sustava (CNS), kognitivne disfunkcije, nervno-mišićnih poremećaja i bolesti, poremećaja i bolesti kosti, tumorske kaheksije, maligne hipertermije, dijabetesa, iznenadne srčane smrti i sindroma iznenadne dječje smrti ili za poboljšanje kognitivne funkcije.
20. Farmaceutski pripravak u skladu s patentnim zahtjevom 10 u kombinaciji s antisens-oligonukleotidom (AO) koji je specifičan za upletanje odsječka u ciljanoj mRNK za bolje preskakanje egzona u rečenoj ciljanoj mRNK, naznačen time, da se koristi za uporabu u liječenju ili prevenciji u skladu s patentnim zahtjevom 11.
21. Farmaceutski pripravak u skladu s patentnim zahtjevom 20, naznačen time, da se koristi u liječenju Duchenne-ove mišićne distrofije (DMD), pri čemu je antisens-oligonukleotid (AO) specifičan za upletanje odsječka od najmanje jednog od egzona DMD gena.
22. Farmaceutski pripravak u skladu s patentnim zahtjevom 21, naznačen time, da je antisens-oligonukleotid specifičan za upletanje odsječka egzona 23, 45, 44, 50, 51, 52 i /ili 53 DMD gena.
23. Postupak priprave u skladu s bilo kojim od patentnih zahtjeva 1-9, naznačen time, da se sastoji od koraka reakcije spojeva formule sa spojem formulesa spojem formulepri čemu Ra je COOR1 ili CN; R1 je C1-C4 alkil, a L je odlazeća skupina kako bi se dobio spoj formule:ipretvaranjem skupine Ra u skupinu R kako bi se dobio spoj formule (I).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625890P | 2012-04-18 | 2012-04-18 | |
| EP12167732.2A EP2708535A1 (en) | 2012-05-11 | 2012-05-11 | Agents for treating disorders involving modulation of ryanodine receptors |
| EP20130164051 EP2653466B1 (en) | 2012-04-18 | 2013-04-17 | Agents for treating disorders involving modulation of ryanodine receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01969B true ME01969B (me) | 2015-05-20 |
Family
ID=49165460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2014-147A ME01969B (me) | 2012-04-18 | 2013-04-17 | Sredstva za lijecenje poremecaja koji ukljucuju modulaciju receptora rijanodina |
Country Status (48)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9725429B2 (en) | 2013-03-15 | 2017-08-08 | Rosalind Franklin University Of Medicine And Science | Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
| US9102645B2 (en) | 2013-03-15 | 2015-08-11 | Rosalind Franklin University Of Medicine And Science | Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
| EP3021841B1 (en) | 2013-07-18 | 2022-11-16 | Baylor College Of Medicine | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia |
| WO2015197562A1 (en) * | 2014-06-23 | 2015-12-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of disorders or diseases associated with ryanodine receptor dysfunction |
| US10071996B2 (en) | 2014-07-30 | 2018-09-11 | Aetas Pharma Co., Ltd. | Optical isomer of 1,4-benzothiazepine-1-oxide derivative, and pharmaceutical composition prepared using same |
| AU2015374155A1 (en) * | 2014-12-30 | 2017-07-20 | Myotherix, Inc. | Novel calcium modulators |
| ES2643856B1 (es) | 2016-05-24 | 2018-08-03 | Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea | Triazoles para la regulación de la homeostasis de calcio intracelular |
| US11426415B2 (en) | 2017-03-06 | 2022-08-30 | Washington University | Treatment for Wolfram syndrome and other endoplasmic reticulum stress disorders |
| WO2019082940A1 (ja) * | 2017-10-25 | 2019-05-02 | 学校法人順天堂 | リアノジン受容体阻害薬 |
| US11026905B2 (en) | 2018-04-19 | 2021-06-08 | Tvardi Therapeutics, Inc. | STAT3 inhibitors |
| CN112367984B (zh) | 2018-04-19 | 2024-05-10 | 特维迪疗法公司 | Stat3抑制剂 |
| MX2022008914A (es) | 2020-01-24 | 2022-08-16 | Tvardi Therapeutics Inc | Compuestos terapeuticos, formulaciones y usos de los mismos. |
| CN116635378A (zh) | 2020-11-06 | 2023-08-22 | 赛特凯恩蒂克公司 | 二环1,4-二氮杂环庚酮和其治疗用途 |
| WO2022150603A1 (en) * | 2021-01-08 | 2022-07-14 | Armgo Pharma, Inc. | Crystalline forms of a ryanodine receptor modulator and uses thereof |
| WO2022246114A2 (en) * | 2021-05-20 | 2022-11-24 | Armgo Pharma, Inc. | Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof |
| EP4433062A1 (en) * | 2021-11-16 | 2024-09-25 | Armgo Pharma, Inc. | Therapeutic compounds |
| US20230302013A1 (en) * | 2022-02-09 | 2023-09-28 | The Trustees Of Columbia University In The City Of New York | METHOD OF TREATING VIRAL-INDUCED COGNITIVE DYSFUNCTION BY TARGETING LEAKY RyR2 CHANNELS |
| EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
| WO2023244946A1 (en) | 2022-06-15 | 2023-12-21 | Tvardi Therapeutics, Inc. | Prodrugs of stat3 inhibitors |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368063B1 (de) * | 1988-11-05 | 1992-06-10 | Bayer Ag | Verfahren zur Kernchlorierung von aromatischen Kohlenwasserstoffen |
| GB9021813D0 (en) * | 1990-10-08 | 1990-11-21 | Ici Plc | Tricyclic heterocycles |
| ZA924760B (en) | 1991-06-28 | 1993-03-31 | Smithkline Beecham Corp | Bicyclic fibrinogen antagonists |
| KR100313649B1 (ko) * | 1992-11-09 | 2002-02-28 | 더 부츠 캄파니 피엘씨 | 신경계질환치료제로서유용한1,4-벤조티아제핀,이의제조방법및이를포함하는약제학적조성물 |
| FR2752017B1 (fr) | 1996-08-01 | 1998-10-16 | Hispano Suiza Sa | Inverseur de poussee de turboreacteur a portes formant ecopes |
| GB9914745D0 (en) | 1999-06-24 | 1999-08-25 | Knoll Ag | Therapeutic agents |
| US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
| US8022058B2 (en) * | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US7879840B2 (en) * | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
| US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
| EE200300168A (et) | 2000-10-30 | 2003-06-16 | Janssen Pharmaceutica N.V. | Tripeptidüülpeptidaasi inhibiitorid, nende valmistamine ja kasutamine ravimina ning neid sisaldav farmatseutiline kompositsioon |
| US7544678B2 (en) | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
| AU2004220548A1 (en) | 2003-03-07 | 2004-09-23 | The Trustees Of Columbia University, In The City Of New York | Type 1 ryanodine receptor-based methods |
| US20090292119A1 (en) * | 2003-10-07 | 2009-11-26 | The Trustees Of Columbia University In The City Of New York | Methods for synthesizing benzothiazepine compounds |
| DE112005003511T5 (de) | 2005-03-23 | 2008-04-17 | Battelle Memorial Institute, Richland | RFID-System mit verbesserter Leistungsfähigkeit |
| US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| WO2007127145A2 (en) | 2006-04-25 | 2007-11-08 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of cardiac arrhythmia in non-human animals |
| WO2008060332A2 (en) | 2006-06-02 | 2008-05-22 | The Trustees Of Columbia University In The City Of New York | Methods for treating or reducing muscle fatigue |
| WO2008021439A2 (en) * | 2006-08-17 | 2008-02-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treatment of cardiac hypertrophy |
| WO2008021432A2 (en) | 2006-08-17 | 2008-02-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treatment of conditions affecting the nervous system |
| WO2008064264A2 (en) | 2006-11-20 | 2008-05-29 | Armgo Pharma, Inc. | In vivo methods for identifying and screening compounds that modulate calstabin binding to a ryanodine receptor |
| KR101260859B1 (ko) | 2008-03-03 | 2013-05-06 | 르 라보레또레 쎄르비에르 | 감마-아미노알킬벤젠으로부터 벤조티아제핀을 제조하는 방법 |
| CN101891706B (zh) * | 2010-04-09 | 2013-05-29 | 复旦大学 | 3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途 |
| WO2012019071A1 (en) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating sarcopenia |
| WO2012019076A1 (en) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury |
| WO2012037105A1 (en) | 2010-09-14 | 2012-03-22 | The Trustees Of Columbia University In The City Of New York | Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases |
-
2012
- 2012-05-11 EP EP12167732.2A patent/EP2708535A1/en not_active Withdrawn
-
2013
- 2013-04-09 JO JOP/2013/0090A patent/JO3070B1/ar active
- 2013-04-12 UY UY0001034742A patent/UY34742A/es not_active Application Discontinuation
- 2013-04-17 TW TW102113668A patent/TWI507399B/zh active
- 2013-04-17 MD MDA20140119A patent/MD4489C1/ro not_active IP Right Cessation
- 2013-04-17 ES ES13164051.8T patent/ES2529890T3/es active Active
- 2013-04-17 DK DK13164051.8T patent/DK2653466T3/en active
- 2013-04-17 NZ NZ701122A patent/NZ701122A/en unknown
- 2013-04-17 RU RU2014145939A patent/RU2644350C2/ru not_active IP Right Cessation
- 2013-04-17 HU HUE13164051A patent/HUE024284T2/en unknown
- 2013-04-17 MX MX2014012575A patent/MX350890B/es active IP Right Grant
- 2013-04-17 PE PE2014001612A patent/PE20142193A1/es active IP Right Grant
- 2013-04-17 JP JP2015506221A patent/JP5965542B2/ja active Active
- 2013-04-17 BR BR112014025670-5A patent/BR112014025670B1/pt active IP Right Grant
- 2013-04-17 WO PCT/EP2013/057958 patent/WO2013156505A1/en active Application Filing
- 2013-04-17 SI SI201330014T patent/SI2653466T1/sl unknown
- 2013-04-17 AP AP2014008011A patent/AP3591A/xx active
- 2013-04-17 UA UAA201412301A patent/UA113759C2/uk unknown
- 2013-04-17 RS RS20140701A patent/RS53711B1/en unknown
- 2013-04-17 KR KR1020147032345A patent/KR101731459B1/ko active Active
- 2013-04-17 EP EP20130164051 patent/EP2653466B1/en active Active
- 2013-04-17 CU CUP2014000119A patent/CU24327B1/es unknown
- 2013-04-17 MY MYPI2014702980A patent/MY167783A/en unknown
- 2013-04-17 AU AU2013248313A patent/AU2013248313B2/en active Active
- 2013-04-17 ME MEP-2014-147A patent/ME01969B/me unknown
- 2013-04-17 PL PL13164051T patent/PL2653466T3/pl unknown
- 2013-04-17 AR ARP130101246A patent/AR090712A1/es unknown
- 2013-04-17 CN CN201380030477.8A patent/CN104350045B/zh active Active
- 2013-04-17 SG SG11201406404YA patent/SG11201406404YA/en unknown
- 2013-04-17 EA EA201401141A patent/EA027922B1/ru not_active IP Right Cessation
- 2013-04-17 CA CA2870599A patent/CA2870599C/en active Active
- 2013-04-17 SA SA113340479A patent/SA113340479B1/ar unknown
- 2013-04-17 PT PT131640518T patent/PT2653466E/pt unknown
- 2013-04-18 US US13/865,359 patent/US20130281512A1/en not_active Abandoned
- 2013-11-11 US US14/076,474 patent/US8853198B2/en active Active
-
2014
- 2014-04-22 HK HK14103808.0A patent/HK1192537A1/zh unknown
- 2014-09-03 US US14/475,980 patent/US20140378437A1/en not_active Abandoned
- 2014-10-07 PH PH12014502256A patent/PH12014502256A1/en unknown
- 2014-10-07 IL IL235043A patent/IL235043A/en active IP Right Grant
- 2014-10-10 TN TN2014000424A patent/TN2014000424A1/fr unknown
- 2014-10-10 CO CO14224913A patent/CO7091184A2/es active IP Right Grant
- 2014-10-13 DO DO2014000230A patent/DOP2014000230A/es unknown
- 2014-10-14 CR CR20140476A patent/CR20140476A/es unknown
- 2014-10-14 CL CL2014002756A patent/CL2014002756A1/es unknown
- 2014-10-15 ZA ZA2014/07499A patent/ZA201407499B/en unknown
- 2014-10-17 GT GT201400222A patent/GT201400222A/es unknown
- 2014-10-30 NI NI201400123A patent/NI201400123A/es unknown
- 2014-11-13 MA MA37525A patent/MA37525B1/fr unknown
- 2014-11-17 EC ECIEPI201427564A patent/ECSP14027564A/es unknown
- 2014-11-18 HR HRP20141113TT patent/HRP20141113T8/hr unknown
- 2014-12-17 CY CY20141101052T patent/CY1115826T1/el unknown
-
2015
- 2015-08-10 HK HK15107691.0A patent/HK1207073A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01969B (me) | Sredstva za lijecenje poremecaja koji ukljucuju modulaciju receptora rijanodina | |
| JP6227707B2 (ja) | Ｍｃｌ‐１を調節する小分子、並びに細胞死、細胞分裂、細胞分化を調節する方法、及び疾患を治療する方法。 | |
| El-Adl et al. | Design, synthesis, molecular docking and anti-proliferative evaluations of [1, 2, 4] triazolo [4, 3-a] quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors | |
| Choi et al. | Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned | |
| JP5628674B2 (ja) | キノン誘導体、医薬組成物、およびそれらの使用 | |
| CN101460164A (zh) | 用于疾病和障碍的化合物 | |
| JP2019527682A5 (me) | ||
| NZ604478A (en) | Fused heterocyclic compounds as ion channel modulators | |
| WO2012013727A1 (en) | Cyclopropylamine derivatives useful as lsd1 inhibitors | |
| PT1692097E (pt) | Derivados de hidroxamato tricíclico e de benzamida, composições e métodos | |
| WO2015134467A1 (en) | Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks | |
| CA2939835A1 (en) | Aminocarbonylcarbamate compounds | |
| CA2941857A1 (en) | An intermediate iodonium ylide and its use in an iodine(iii)-mediated radiofluorination process | |
| JP2016512198A5 (me) | ||
| Shiue et al. | Synthesis of N, N-dimethyl-2-(2-amino-4-[18F] fluorophenylthio) benzylamine as a serotonin transporter imaging agent | |
| JP2005518444A (ja) | アリールスルホン誘導体 | |
| ITBO20090078A1 (it) | Composti per il trattamento del tumore alla prostata e procedimenti per la loro sintesi | |
| WO2017181974A1 (zh) | 五元杂环类化合物及其制备方法、药物组合物和用途 | |
| Varlow et al. | Radiofluorination of oxazole-carboxamides for preclinical PET neuroimaging of GSK-3 | |
| CN106413713A (zh) | 用作药物的吡吲哚对映异构体的药学上可接受的盐 | |
| PL181936B1 (pl) | N itrob en zam id y, sposó b ich w ytw arzan ia o raz ko m p ozycja farm aceu tyczn a je zaw ierajaca PL PL PL PL PL PL PL PL | |
| JP2019085364A (ja) | ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途 | |
| Hugenberg et al. | Radiolabeled hydroxamate-based matrix metalloproteinase inhibitors: how chemical modifications affect pharmacokinetics and metabolic stability | |
| CN104356010A (zh) | 一种普萘洛尔的改进制备方法 | |
| JP2013535435A (ja) | 造影剤の製造方法 |